Insights from 2023 SABCS


 

SABCS 2023 Insights: "CompassHER2 RD Trial - Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2+ Invasive BC"

290 views
December 15, 2023
0 Comments
Login to view comments. Click here to Login
Videos